Investigation Of Transgenic Mouse Models Of Type 2 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$412,200.00
Summary
Type 2 diabetes is a common condition characterised by high blood glucose, that afflicts 700,000 Australians. It causes blindness, kidney failure and an increased risk of heart attack and stroke. despite intensive study over many years, the reasons for the elevated blood glucose in this condition are not fully understood. Several abnormalities can contribute to the high glucose and different researchers have proposed different defects as the initial cause. It has proven difficult to unravel the ....Type 2 diabetes is a common condition characterised by high blood glucose, that afflicts 700,000 Australians. It causes blindness, kidney failure and an increased risk of heart attack and stroke. despite intensive study over many years, the reasons for the elevated blood glucose in this condition are not fully understood. Several abnormalities can contribute to the high glucose and different researchers have proposed different defects as the initial cause. It has proven difficult to unravel the sequence of events in the evolution of the syndrome because high glucose can cause insulin resistance and a defect in insulin secretion, both of which can lead to high blood glucose. One approach to study the consequences of specific defects is to genetically engineer them. The aims of this project are to: 1. make a mouse with reduced ability to store glucose in muscle. 2. test the metabolic consequences of a defect in the manufacture of glycogen (starch) in muscle. 3. study the effects of combining a defect in glucose storage with one that results in an oversupply of glucose. 4. study the effects on a mouse with a genetic predisposition for failure of beta cells (insulin making cells) of a defect in muscle glucose storage and over production of glucose. A successful completion of this grant will greatly enhance our understanding of how blood glucose is increased in Type 2 diabetes.Read moreRead less
Protein Tyrosine Phosphatases In The Regulation Of Insulin Receptor Signalling And Glucose Uptake
Funder
National Health and Medical Research Council
Funding Amount
$425,250.00
Summary
The key pathological feature of type II diabetes is the lack of cellular response to normal levels of circulating insulin. Insulin binding to its cell surface transmembrane receptor initiates a cascade of events known as cellular signalling that results in amongst other things in the uptake of glucose. Protein tyrosine phosphatases (PTPs) are key negative regulators of insulin-induced signalling events and their inhibition with broad based chemical inhibitors can mimic several actions of insulin ....The key pathological feature of type II diabetes is the lack of cellular response to normal levels of circulating insulin. Insulin binding to its cell surface transmembrane receptor initiates a cascade of events known as cellular signalling that results in amongst other things in the uptake of glucose. Protein tyrosine phosphatases (PTPs) are key negative regulators of insulin-induced signalling events and their inhibition with broad based chemical inhibitors can mimic several actions of insulin and lower blood glucose levels in both normal and diabetic rats. This proposal will examine the roles of PTPs and in particular TCPTP and PTP1B in insulin receptor-mediated signalling and glucose uptake. Moreover we will explore the role of TCPTP in alternate insulin receptor-independent processes for glucose uptake. Our studies will shed light on processes important for the regulation of glucose uptake. Moreover our studies may lead to the development of drugs capable of inhibiting PTPs such as TCPTP, that may allow for enhanced glucose uptake and have therapeutic use in the treatment of type II diabetes.Read moreRead less